Synta Pharmaceuticals Corp. SNTA was a big mover last session, as the company saw its shares rise 9.5% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This reverses the recent trend for the company as the stock is now down 26.24% in the past one-month time frame.
In the last 30 days, the company witnessed 2 downward estimate revisions and the Zacks Consensus Estimate, pegged at a loss, has widened over the same timeframe, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward to see if this recent high can last.
Synta Pharmaceuticals currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
Some other players in the healthcare industry include Alexion Pharmaceuticals, Inc. ALXN, with a Zacks Rank #1 (Strong Buy) along with Actelion Ltd. (ALIOF) and Cambrex Corporation.CBM holding a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
ACTELION LTD (ALIOF): Get Free Report
ALEXION PHARMA ALXN: Free Stock Analysis Report
CAMBREX CORP CBM: Free Stock Analysis Report
SYNTA PHARMACT SNTA: Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
